Key result
Participation in cardiac disease management programs significantly improved adherence to cardiac medications and increased appropriate LDL control by 36% relative to baseline (P<0.0001).
Why the study?
Does participation in cardiac disease management programs improve adherence to evidence-based medicine and LDL control in patients with CHD and/or HF?
Observational (n=20,202)
Does participation in cardiac disease management programs improve adherence to evidence-based medicine and LDL control in patients with CHD and/or HF?
p-value: p=<0.0001
Participation in cardiac disease management programs significantly improves patient adherence to guideline-directed medical therapy and lipid control.
DM programs may aid adherence in CHD/HF; leaves open impact on outcomes in prospective trials.
Adherence to cardiovascular disease standards of care is critically important for minimizing the risk of mortality and morbidity for individuals with coronary heart disease (CHD) and heart failure (HF). The purpose of this study was to assess the ability of cardiac disease management (DM) programs to assist members with their adherence to evidence-based medicine for cardiovascular diseases. A total of 20,202 members with CHD and/or HF were evaluated 12 months prior to the start of DM programs and during their first 12 months of participation in the programs. Members were assessed for their adherence to appropriate cardiac medications. In addition, low-density lipoprotein (LDL) testing rates and clinical control of LDL values (defined as <100 mg/dL) were measured. The association between LDL control and use of lipid-lowering statins also was assessed. During participation in the cardiac programs, members achieved significant improvement in their adherence to angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and beta-blockers (P < 0.0001). The cardiac population also achieved a significant increase in LDL testing rates and statin use (P < 0.0001). More members attained appropriate LDL control in year 1 compared to baseline (36% relative increase), and this improvement was associated with a 40% relative increase in statin use. In summary, participation in these cardiac DM programs assisted members to improve their adherence to cardiac medications and standards of care guidelines. Such improvements in cardiovascular disease care are likely associated with improved quality of life and reduced risk for mortality.
No takes yet. Share an insight, caveat, or question.
Coberley et al. (2008) conducted an observational in Coronary heart disease and/or heart failure (n=20,202). Cardiac disease management programs vs. 12 months prior to program start (baseline) was evaluated on Adherence to appropriate cardiac medications and LDL testing/control (p=<0.0001). Participation in cardiac disease management programs significantly improved adherence to cardiac medications and increased appropriate LDL control by 36% relative to baseline (P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: